newsfilter
← Latest News
Business Wire·

Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting

No new safety signals identified during additional three years of extended use Organon holds exclusive global licensing rights to MIUDELLA Organon (NYSE:OGN), a global healthcare company with a mission to